Moderate dose melatonin for the abatement and treatment of delirium in elderly general medical inpatients: study protocol of a placebo controlled, randomised, double blind trial

Table 1 Schedule of Procedures

Procedure	Entry (D0)	Daily 1–5 (on treatment)	Day 6	Final Visit (Day 7)
Consent	○
Age	○
Gender	○
Electrolytes	○
Liver function	○
MMSE	○	○	○	○
Digit Span	○	○	○	○
CAM	○	○	○	○
MDAS	○	○	○	○
Motor type	○
CMI	○
IQCODE	○^a
GDS-15	○
Katz ADL	○
Presence of Restraints		○	○	○
# Falls		○	○	○
# Pressure areas	^b	○	○	○
Rescue medication		○	○	○
Adverse events			○	○
Review INR	○^c	○^c

^aIdeally the IQCODE will be measured at entry but can be measured at any point
^bInitial number and location will be recorded at entry in order to derive the number of new areas at each subsequent visit
^cIf participant is on warfarin, we will review the INR that has been performed every 1–2 days as is standard protocol for acutely unwell inpatients when warfarinised

ISSN: 1471-2318